Даниил Талан

How exactly does the curation process work?

Any person can start a database around a topic. For example web3 applications that have been audited, news articles about Russia, or restaurants in New York City. The person that starts and defines the criteria for a database is called curator. Anyone can start a database.

Other people then submit data that they think fits the criteria of the database. We call these people scouts. When a scout submits content they have to pay one token (a small amount), which is refunded if their data is accepted into the database. Before the data is accepted into the database, if another scout sees the data and thinks the curator won’t accept it they can vote with two tokens to reject the data. Another scout can then vote with four tokens to keep the data in. The token cost continues to double each time to vote the data in or out of the database.

This process continues until someone on one side stops staking or the pool of tokens exceeds a threshold. If one side stops staking tokens, after X minutes (X is defined by the curator when the database is minted) the content is either accepted or rejected depending on which side staked last.

On the other hand, if the data is contested by many people, and the pool of tokens crosses a certain threshold, the curator decides if the data should be accepted or rejected from the database.

The winning faction gets the losing faction's tokens. The curator takes a cut of the pool for doing work deciding if the content should be accepted or rejected.

Once data has been accepted into the database, scouts and the curator get access to a percentage of the token that database generates based on viewership.

OrCam’s mission is to harness the power of artificial vision by incorporating pioneering technology into a wearable platform which improves the lives of individuals who are blind, visually impaired, and have reading difficulties.

OrCam was jointly founded in 2010 by Prof. Amnon Shashua and Mr. Ziv Aviram, who are also the co-founders of Mobileye, the collision avoidance system leader and autonomous driving innovator. The original OrCam MyEye device was launched in 2015, and the next generation OrCam MyEye 2.0 was launched in 2017.

Reaching New Destinations

Pliant Therapeutics is a clinical-stage biopharmaceutical company leading the way in developing new treatments for fibrotic diseases. As fibrosis is a complex disease, few available treatments for fibrosis exist today. We are committed to advancing novel treatments and prepared to change the fibrosis treatment landscape.

Pliant is diving deep to understand the molecular drivers of fibrotic diseases to unlock potentially safer, and more effective therapies for patients.

Mission

Build the leading fibrosis company by combining world class expertise in fibrosis-biology, chemistry and technology to develop best-in-class,

tissue-specific, inhibitors of fibrotic diseases.

We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.

Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.

Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy.

Prima System features a miniaturized and totally wireless sub-retinal PRIMA implant, a pocket computer equipped with breakthrough algorithms, and a pair of glasses which captures the visual scene.

For the novel breakthrough Prima system, the exclusive transfer of the patented technology was granted by Stanford’s University to Pixium Vision to develop and industrialize the PRIMA bionic vision system.

Pixium Vision is currently conducting in France and in the United States, two feasibility clinical trials with PRIMA, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD), for which there is no treatment available to date.

Altris AI (Altris, Inc) is a company which applies computer vision and deep learning trained algorithms to build innovative ophthalmology diagnosis real-time support platform for the automatic, structural and quantitative analysis and detection of glaucoma, age-related macular degeneration, diabetic retinopathy and other retinal diseases on Optical Coherence Tomography (OCT) scans by learning from a large dataset of clinical cases.

The company has accumulated and legally owns one of the most massive anonymized databases of the retina, optic nerve scans, and images as well as clinical data. We continue increasing our dataset daily in our ophthalmology center with OCT, OCT-Angio scans.

Altris AI’s OCT algorithms have been trained using anonymized OCT retinal scans collected during more than 12 years and are able to detect more than 100 pathological signs, retinal diseases and conditions. Currently, Altris AI’s solution is available in web and mobile version for structural retina analysis. The model shows the high level of performance with multi-disease classification accuracy more than 96%.

ANBITION activities are focused on developing new molecules and technologies useful for treating or diagnosing angiogenesis-related diseases, including eye neo-vascular disease such as macular oedema, wet age-related macular degeneration and diabetic retinopathy.

MyopiaX® is an application for smartphones that provides a treatment to slow the progression of myopia in children and adolescents. Used together with a virtual reality headset and a Bluetooth controller, MyopiaX® is an innovative, non-invasive method to control myopia that is portable, fun, and easy for children to use.

Use the MyopiaX® app to start a session, keep track of usage and performance to optimize treatment, customize daily availability, and much more. Each session with MyopiaX® delivers a light stimulus on top of the virtual reality game. The goal is to increase dopamine levels in the retina to slow the progression of myopia.

EyeQue believes that clear vision is a right, not a privilege. We develop technologies that let people stay on top of their vision. We encourage everyone to incorporate EyeQue’s safe, affordable, and convenient at-home vision solutions as part of their comprehensive eye health regimen.

Focused on Partnering with Eye Doctors

EyeQue collaborates with eye doctors to deepen engagement with their patients. With our unique at-home solutions, doctors help patients update their prescription between appointments, track treatment effectiveness against a specific condition, and monitor patient progress after a procedure.

EyeQue helps eye doctors adopt telemedicine to grow their practice and supports consumer interest in self-care. We help people find eye doctors through our partnership with EyecareLive, a national eyecare telemedicine referral service.

At EyeYon, we are building a clearer future

EyeYon Medical Ltd. is a pioneer in ophthalmologic medical devices, focusing on developing cornea-focused sight-saving solutions for more than a decade. We believe in challenging technology barriers to save the vision of millions of eyes worldwide.

EyeYon Medical is driven by a multi-disciplinary team of visionaries along with investors who see a future world with a new standard of corneal treatments, saving the sight of all those suffering from serious cornea-related conditions.

Nano Retina is an innovative company developing advanced nanotechnology devices intended to restore functional vision to blind individuals. Nano Retina was founded in 2009 by two visionary medtech experts— Yossi Gross, a serial entrepreneur, inventor and co-founder of Rainbow Medical, and Jim von Ehr, a leader in the field of nanotechnology and founder and CEO of Zyvex Labs.

Based on sound scientific knowledge and rigorous research, the team at Nano Retina is developing a device that will provide functional vision to people who are blind due to retinal degenerative disease.

While a relatively young company, Nano Retina has made giant technological leaps leveraging the cumulative experience of its team members. The Nano Retina team of engineers, physicists, ophthalmologists, low vision specialists and regulatory experts has over 200 years of combined experience.

Nano Retina has offices in Herzliya, Israel, and partners globally with distinguished research centers and technology manufacturers.

Next-Generation Antibody Therapies

We develop our therapeutic candidates using our DiversImmune™ platform. Our antibody discovery platform enables us to generate antibodies against traditionally difficult targets. The resulting antibodies are high affinity, high specificity antibody “building blocks” with drug-like properties against a wide range of therapeutic targets. Our platform then enables us to assemble these building blocks into a variety of formats, tailored for each disease area.

We are focusing on areas where we can help mankind affected by serious disease and where monoclonal antibodies can play a leading role. This includes immuno-oncology/cancer, eye, infectious, and autoimmune disease.

Surface Ophthalmics, Inc. is a pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular diseases. We are striving to solve key patient needs in eye care through leveraging deep expertise, a bold approach, an eye toward efficiency, and a clear, differentiated clinical advantages. Our current drug pipeline consists of three proprietary drug candidates, all utilizing Klarity®, a patented delivery vehicle. We are led by an experienced and proven management team and board of directors with over 80 years of ophthalmology related professional experience.

Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will be fundamental to help the world in rethinking what's possible with vaccines.

Vaxxas' approach which has been validated in human clinical studies can enhance the efficiency and effectiveness of a vaccine's immune response. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain".

Vaxxas is targeting initial applications in infectious disease and oncology and has forged collaborations with leading global organizations in vaccine commercialization, including Merck/MSD, the United States Biomedical Advanced Research and Development Authority (BARDA), the World Health Organization (WHO), and the Bill and Melinda Gates Foundation.

WHO WE ARE

The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase 1 through phase 3) and global regulatory interactions.

WHAT WE DO

The institute focuses on programs aimed at reducing the burden of TB, malaria, diarrheal diseases, and maternal, newborn, and child illnesses.

As an affiliate of the Bill & Melinda Gates Foundation, the institute’s programs are focused on disease and health areas of primary focus at the foundation. The interventions under study and development are derived from sources both within and external to the foundation.

Hemab Therapeutics

Despite tremendous innovation in hemophilia, treatment of rare bleeding and thrombotic disorders is still limited to blood transfusions and acute treatments.

Hemab leverages key insights into the treatment of bleeding and thrombosis to overcome longstanding hurdles in creating a preventative treatment for patients suffering from these disorders. Our lead asset, HMB-001, will initially target Glanzmann Thrombasthenia, enabling patients to proactively manage the disease for the first time. HMB-001 binds and recruits endogenous factor VIIa (FVIIa) to the site of vascular injury to overcome defects in patients’ ability to form healthy clots. Built on the heritage of recombinant FVIIa, our technology is prime for widespread indication expansion to other rare bleeding disorders

People living with rare and devastating diseases are our Guiding Star. We believe it is our responsibility to listen to, understand, and change the lives of patients and those who work tirelessly to help them.

We continue to deepen our understanding of rare disease, which began with our pioneering work in complement biology. This knowledge allows us to innovate and evolve into new areas, where there is great unmet need and opportunity to help patients and families fully live their best lives.

We’ve delivered transformative medicines for people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D).

Making science’s hardest obstacles our highest priority.

Frustrated by the fact that so many devastating diseases still lack adequate treatments, we’ve made it our mission to discover, develop, manufacture, and deliver therapies that meaningfully improve the lives of patients.

Our success depends on rallying the best people, partners, and science. It hinges on fearlessly creating paths forward no one has attempted before. And of course, it means striving to develop and deliver the truly transformational.

Following the science wherever it goes.

Developing and delivering transformative therapies starts with access to high-quality product candidates. The trick is finding them. At Rallybio, we believe we have two unique advantages. First, our decades of experience in drug discovery, research, development, regulatory strategy, and manufacturing help us more effectively source, identify, and evaluate therapeutic targets and product candidates with a high probability of success. At the same time, we have an extensive network of relationships with leaders in industry and in academic clinical centers worldwide who know just what we’re looking for—and what we are capable of achieving.

Priothera is leading the way in developing mocravimod, a S1P receptor modulator as an adjunctive immune therapy to allo-HSCT.

S1P receptor modulators largely reduce the egress of T-cell subsets from lymphatic tissues and are thereby suggested to inhibit graft-versus-host disease (GvHD) while at the same time enhancing graft-versus-leukemia benefits in patients receiving allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Priothera is developing mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT. Mocravimod has been studied in pre-clinical stem cell transplantation models and has shown a survival benefit. In addition, mocravimod was safe and well tolerated and showed efficacy in patients with hematological malignancies undergoing allo-HSCT.